

**INVESTIGATIONAL PLAN/PROTOCOL**

**The Portable Organ Care System (OCS™) Heart For Resuscitation, Preservation and Assessment of Hearts from Donors after Circulatory Death Continued Access Protocol (OCS DCD Heart CAP)**



**Number OCS-CAR-08242020**

<b>Sponsor:</b>	TransMedics, Inc. 200 Minuteman Road, Suite 302 Andover, MA 01810
<b>Sponsor Primary Contact:</b>	[REDACTED] <a href="#">m</a>
<b>Sponsor Secondary Contact:</b>	[REDACTED]

**CONFIDENTIAL – PROPRIETARY INFORMATION**

Protocol Rev	Issue Date
1.0	16-September-2020

## TABLE OF CONTENTS

<b>OCS DCD HEART CAP SYNOPSIS.....</b>	<b>5</b>
<b>1. INTRODUCTION AND BACKGROUND INFORMATION .....</b>	<b>8</b>
1.1. Heart Transplantation and Current Clinical Challenges .....	8
<b>2. SUMMARY OF PRIOR TESTING AND INVESTIGATIONS.....</b>	<b>13</b>
2.1. OCS Heart Preclinical Testing .....	13
2.2. Preclinical Animal Testing of OCS Heart System for DCD hearts .....	13
2.2.1. Iyer, et al., 2015.....	13
2.2.2. García Sáez, et al., 2015.....	14
2.3. OCS Heart Clinical Testing for DCD Hearts Outside the U.S. ....	15
2.3.1. Messer, et al., 2017 .....	15
2.3.2. Dhital, et al. (2015 and 2017) .....	16
2.3.3. García Sáez, et al. (2016, 2017) .....	17
2.3.4. Chew, et al. (2019).....	17
2.4. Additional Clinical Studies of the OCS Heart System for Standard and Extended Criteria and DCD Donor Hearts .....	18
2.5. Overall Summary of Clinical Data to Support OCS DCD Heart CAP .....	20
<b>3. DEVICE DESCRIPTION.....</b>	<b>20</b>
3.1. Description of Major Components.....	20
3.1.1. OCS Heart Console.....	20
3.1.2. Heart Perfusion Set (HPS) .....	21
3.1.3. OCS Heart Solution Set .....	21
3.1.4. Mode of Action - Overview .....	22
<b>4. TRIAL OBJECTIVES.....</b>	<b>23</b>
4.1. Trial Design.....	23
4.2. Trial Size and Subject Follow-up.....	23
<b>5. TRIAL ENDPOINTS.....</b>	<b>23</b>
5.1. Primary Endpoint.....	23
5.2. Secondary Endpoint .....	23
5.3. Safety Endpoint .....	23
5.4. Other Endpoints .....	23
<b>6. TRIAL POPULATION .....</b>	<b>24</b>
6.1. DCD Donor Eligibility Criteria .....	24
6.2. Recipient Eligibility Criteria .....	24
6.3. DCD Heart Subject Enrollment and Screen Failures.....	25
<b>7. PRE-OPERATIVE TRIAL PROCEDURES .....</b>	<b>26</b>
7.1. Subject Identification .....	26
7.2. Recipient Day of Transplant Assessment .....	26
7.3. Donor Screening and Acceptance for DCD Hearts .....	26
7.4. DCD Donor Heart Retrieval and OCS Preservation and Assessment .....	26
7.4.1. Donor Heart Acceptance/Rejection for Transplantation after OCS Preservation .....	26
<b>8. TRANSPLANT, IMMEDIATE POST-OPERATIVE AND LONG-TERM FOLLOW-UP .....</b>	<b>27</b>
8.1. Transplant Details.....	27
8.2. Post-transplant Functional Assessments Day 0 – Day 30.....	27
8.3. Long-term Follow-up: 6 and 12 Months .....	28
8.4. Evaluation of Adverse Events .....	28
8.4.1. Serious Adverse Events (SAEs).....	28

8.4.2.	Heart Graft-Related SAEs (HGRSAEs) .....	28
8.4.3.	Unanticipated Adverse Device Effect (UADE).....	28
8.4.4.	Anticipated SAEs.....	29
8.4.5.	Reporting of Adverse Events .....	30
8.4.6.	Relationship of an SAE or HGRSAE to OCS Heart System .....	30
8.4.7.	Severity .....	30
8.4.8.	Pre-Existing Conditions.....	30
<b>9.</b>	<b>OCS HEART TRAINING RUNS .....</b>	<b>31</b>
<b>10.</b>	<b>STATISTICAL METHODS.....</b>	<b>31</b>
10.1.	General .....	31
10.2.	Analysis Populations.....	31
10.2.1.	DCD Heart Transplanted Recipient Population .....	31
10.2.2.	OCS Heart Population .....	31
10.2.3.	Modified Intend-to-Treat (mITT) Population.....	31
10.3.	Statistical Analysis .....	31
10.3.1.	Primary Endpoint.....	31
10.3.2.	Secondary and Other Endpoints.....	32
10.4.	Safety .....	32
10.5.	Sample Size Determination .....	32
<b>11.</b>	<b>RISK ANALYSIS.....</b>	<b>32</b>
11.1.	Potential Risks .....	33
11.2.	Manner in Which the Potential Risks Have Been Minimized .....	33
11.3.	Potential Benefits .....	34
11.4.	Risks Benefit Ratio .....	34
<b>12.</b>	<b>DEVICE/SITE MANAGEMENT.....</b>	<b>34</b>
12.1.	Packaging and Labeling .....	34
12.2.	Storage .....	34
12.3.	Accountability.....	35
12.4.	Device Complaints and Malfunctions.....	35
<b>13.</b>	<b>REGULATORY/ETHICS .....</b>	<b>35</b>
13.1.	Institutional Review Boards (IRB).....	35
13.2.	Informed Consent.....	35
<b>14.</b>	<b>DATA COLLECTION/RECORDS/REPORTS.....</b>	<b>35</b>
14.1.	Investigator Records.....	35
14.2.	Investigator Reports .....	36
14.3.	Data Collection .....	37
14.4.	Source Documents .....	37
14.5.	Archiving of Records.....	37
<b>15.</b>	<b>CLINICAL MONITORING .....</b>	<b>37</b>
15.1.	Monitoring.....	37
15.2.	Site Initiation Visit .....	38
15.3.	Periodic Monitoring Visits .....	38
15.4.	Frequency of Monitoring Visits .....	39
15.5.	Study Close-out Visit .....	39
15.6.	Protocol Deviations .....	39
15.7.	Clinical Events Committee (CEC) .....	39
15.8.	Data Safety Monitoring Board & Stopping Rules .....	39

15.9. Investigator Training ..... 40

16. CONFIDENTIALITY ..... 40

17. AMENDMENT POLICY ..... 40

18. REFERENCES ..... 41

APPENDIX 1: ISHLT CONSENSUS MANUSCRIPT HEART PRIMARY GRAFT DYSFUNCTION (PGD)  
(KOBASHIGAWA, ET AL., 2014) ..... 43

APPENDIX 2: SCHEDULE OF CLINICAL ASSESSMENTS ..... 44

APPENDIX 3: DRAFT PATIENT INFORMED CONSENT FORM TEMPLATE ..... 45

APPENDIX 4: DRAFT ELECTRONIC CASE REPORT FORMS ..... 46

## OCS DCD HEART CAP SYNOPSIS

<b>Protocol Title</b>	The Portable Organ Care System (OCS™) Heart for Resuscitating, Preserving and Assessing Hearts Donated after Circulatory Death Continued Access Protocol (OCS DCD Heart CAP)
<b>Objectives</b>	To enable continued clinical access to DCD heart transplantation in the U.S. and to continue to collect additional data on the performance of the OCS Heart System to resuscitate, preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation.
<b>Trial Design</b>	A prospective, single arm, continued access protocol.
<b>Trial Size</b>	A maximum of 25 participating sites transplanting up to 90 DCD heart recipients.
<b>Screening and Treatment</b>	<p>Donor DCD hearts that may be acceptable for transplant will be screened for trial eligibility. Eligible DCD donor hearts will be preserved and assessed with the Organ Care System (OCS). After OCS preservation and assessment, DCD donor hearts will be evaluated for acceptability for transplantation according to prespecified criteria.</p> <p>Primary heart transplant candidates will be screened for trial eligibility. Eligible heart transplant candidates will receive OCS preserved DCD donor hearts that have been deemed clinically acceptable for transplantation following preservation by the treating transplant clinical team according to specified criteria.</p>
<b>DCD Donor Heart Eligibility Criteria</b>	<p><b>Inclusion</b></p> <ul style="list-style-type: none"> <li>• Maastricht Category III DCD donor, defined as expected death after the withdrawal of life-supportive therapy (WLST)</li> <li>• Donor age 18-49 years old inclusive</li> <li>• Warm ischemic time (WIT) ≤ 30 mins, with warm ischemic time defined as: Time from when mean systolic blood pressure (SBP) is &lt; 50 mmHg or peripheral saturation &lt; 70% to aortic cross-clamp and administration of cold cardioplegia in the donor.</li> </ul> <p><b>Exclusion</b></p> <ul style="list-style-type: none"> <li>• Previous cardiac surgery;</li> <li>• Known coronary artery disease;</li> <li>• Cardiogenic shock or myocardial infarction;</li> <li>• Sustained terminal EF of ≤ 50%; or</li> <li>• Significant valve disease except for competent bicuspid aortic valve.</li> </ul>
<b>Recipient Eligibility Criteria</b>	<p><b>Inclusion</b></p> <ul style="list-style-type: none"> <li>• Primary heart transplant candidates</li> <li>• Age ≥ 18 years old</li> <li>• Signed: (1) written informed consent document; (2) authorization to use and disclose protected health information; and (3) consent to TransMedics' use of recipients' UNOS/OPTN data and recipients' INTERMACS data.</li> </ul> <p><b>Exclusion</b></p> <ul style="list-style-type: none"> <li>• Prior solid organ or bone marrow transplant</li> <li>• Chronic use of hemodialysis or diagnosis of chronic renal insufficiency</li> <li>• Multi-organ transplant.</li> </ul>
<b>DCD Donor Heart on OCS Transplant Criteria</b>	<p><b>Accept for Transplantation</b></p> <p>Donor hearts preserved on the OCS Heart System to be maintained within the following target ranges:</p> <ul style="list-style-type: none"> <li>• Stable or downward trending lactate after initial adjustments of the OCS Heart perfusion parameters to achieve adequate perfusion to the donor heart</li> <li>• Stability of OCS Heart perfusion parameters within range: <ul style="list-style-type: none"> <li>○ AOP 40-100 mmHg</li> </ul> </li> <li>• Transplanting surgeon and/or heart failure cardiologist must clinically accept the OCS perfused donor heart for transplant.</li> </ul> <p><b>Reject for Transplantation</b></p> <ul style="list-style-type: none"> <li>• Transplanting surgeon and/or heart failure cardiologist clinically unsatisfied with donor heart condition/performance on the OCS Heart System at final evaluation</li> </ul>

	<ul style="list-style-type: none"> <li>Unstable and rising arterial lactate despite maneuvers to optimize perfusion parameters.</li> </ul> <p>Note: Certain donor hearts may require perfusion with parameters outside of these guidance ranges. Acceptance for transplantation should be primarily based on an acceptable lactate trend.</p>
<b>Primary Endpoint</b>	<ul style="list-style-type: none"> <li>Patient survival at 6 months post-transplant.</li> </ul>
<b>Secondary Endpoint</b>	<ul style="list-style-type: none"> <li>Utilization Rate, defined as the number of eligible DCD donor hearts that met the warm ischemic time limit above and were instrumented on the OCS Heart System that meet the acceptance criteria for transplantation after OCS Heart preservation divided by the total number of eligible DCD donor hearts that met the warm ischemic time limit above and were instrumented on the OCS Heart System.</li> </ul>
<b>Other Endpoints</b>	<ul style="list-style-type: none"> <li>Patient and graft survival at 30 days post-transplant</li> <li>Patient and graft survival at 30 days or initial hospital discharge, if later than 30 days</li> <li>Severe heart primary graft dysfunction (PGD) (left or right ventricle) (not including rejection or cardiac tamponade) according to ISHLT consensus manuscript (as defined in <a href="#">Appendix 1</a> of this protocol)</li> <li>Use of post-transplant mechanical circulatory support (LVAD, RVAD, BiVAD) for &gt; 72 hours immediately post-transplant.</li> <li>Patient survival at 1 year after transplant.</li> </ul>
<b>Safety Endpoint</b>	<p>The safety endpoint is defined as the incidence of heart graft-related Serious Adverse Events (HGRSAEs) in the first 30 days post-heart transplantation in the DCD Heart Transplanted Recipient Population, defined as the following adverse events (at most one per type):</p> <ul style="list-style-type: none"> <li>Moderate or Severe heart PGD (left or right ventricle) (not including rejection or cardiac tamponade) according to ISHLT consensus manuscript (as defined in <a href="#">Appendix 1</a> of this protocol).</li> <li>Primary graft failure requiring retransplantation.</li> </ul>
<b>Follow-up</b>	<ul style="list-style-type: none"> <li>All patients will be followed for 12 months in the study database; then through 5 years via the UNOS/OPTN database.</li> </ul>
<b>Statistical Methods</b>	<p>The <b>DCD Heart Transplanted Recipient Population</b> will consist of all eligible recipients who are transplanted with an eligible DCD donor heart that met the warm ischemic time limit defined above, preserved on OCS and met the transplantability criteria. The analyses of all effectiveness and safety endpoints, except the utilization rate, will be based on the DCD Heart Transplanted Recipient Population.</p> <p>The <b>OCS Heart Population</b> will consist of all eligible donor hearts that met the warm ischemic time limit above and were instrumented on the OCS Heart System. The analysis of utilization rate will be based on the OCS Heart population.</p> <p>The <b>modified intend-to-treat (mITT) population</b> will consist of all recipients who are transplanted according to this protocol. The mITT analysis will be considered secondary analyses of all effectiveness and safety endpoints except the rate of donor heart utilization.</p> <p>The primary endpoint will be summarized using counts and percentages and an exact 95% confidence interval for the true percentage based on the binomial distribution.</p> <p>Each other endpoint will be summarized using counts and percentages and an exact (Clopper-Pearson) 95% confidence interval for the true percentage based on the binomial distribution.</p> <p>The rate of donor hearts that were successfully transplanted after preservation and assessment on the OCS Heart System (i.e., donor heart utilization) will be summarized using counts and percentages and an exact 95% confidence interval for the true percentage based on the binomial distribution.</p> <p>Serious Adverse Events (SAEs) and Heart Graft-related Serious Adverse Events (HGRSAEs) will be collected within the first 30 days post-transplant and the mean number of HGRSAEs per subject will be summarized using descriptive statistics. HGRSAEs are defined as the following adverse events (at most one per type): Moderate or Severe heart PGD (left or right ventricle) (not including rejection or cardiac tamponade) according to ISHLT consensus manuscript (as defined in <a href="#">Appendix 1</a> of this protocol) and primary graft failure requiring retransplantation.</p>

	SAEs and HGRSAEs will also be tabulated using counts and percentages alone and in regards to the relationship of the HGRSAE to the device, and the severity of the HGRSAE.
<b>Determination of Sample Size</b>	This is a continued access protocol and does not have a statistically determined sample size.
<b>Trial Sponsor</b>	TransMedics, Inc. 200 Minuteman Road, Suite 302 Andover, MA, USA 01810

## **1. INTRODUCTION AND BACKGROUND INFORMATION**


The OCS DCD Heart Continued Access Protocol (CAP) is a continuation of the OCS DCD Heart trial which recently completed enrollment. The purpose of the OCS DCD Heart CAP is to enable continued clinical access to DCD heart transplantation in the U.S. and to continue to collect additional data on the performance of the OCS Heart System while patient follow-up is completed and the marketing application for the OCS Heart System for DCD donor hearts is prepared and undergoes review at the FDA.

### **1.1. Heart Transplantation and Current Clinical Challenges**

Heart transplantation is the gold standard and the most cost-effective treatment for end-stage heart failure (Hunt and Haddad 2008). While the demand for heart transplantation globally has increased significantly each year, the utilization or recovery of available donor hearts for transplantation has been limited. Based on the Organ Procurement and Transplantation Network (OPTN) 2014 report, 4,323 (approximately 50%) consented, donor hearts in the U.S. are not recovered annually, depriving thousands of patients the gift of new hearts to treat their end-stage heart disease (Israni, et al., 2016) (see [Figure 1](#)).




**Figure 1: Heart Organ Use in the U.S. in 2014 (Figure DOD7.5 from OPTN/SRTR Annual Data Report 2014) (Israni, et al., 2016)**



The donor organ shortage has also led to an increasing utilization of Mechanical Circulatory Support (MCS) devices, which are being used as either a “Bridge to Transplant” or as a replacement for organ transplantation (“Destination Therapy”) (Figure 2).

**Figure 2: MCS devices implanted in U.S. patients, 2006-September 2017. From INTERMACS Quarterly Statistical Report, 2017. (Kirklin, et al., 2017)**




MCS devices are being implanted in patients who are candidates for heart transplant (so-called Bridge to Transplant (BTT) indication) solely as a result of the donor organ shortage. The American Heart Association, ISHLT, The American Transplant Society and investigators in the U.S. and worldwide recognize heart transplant as the “gold standard” treatment and the only curative therapy for end stage heart failure. (Peura, et al., 2012; Katz, et al., 2015; Wilhelm, 2015; Mancini, 2010; Kobashigawa, et al., 2017). In fact, this shortage of donor organs results in approximately 16% of the Status 1A patients listed on the national waiting list for heart transplantation dying or deteriorating so much that they were removed from the waiting list at 12 months ([Table 1](#)). Status 1A patients include those who were implanted with MCS devices while awaiting transplant.

**Table 1: United Network for Organ Sharing (UNOS) Statistics on Waiting List Mortality (*Organ: Heart*)  
Waiting List Death Rates within 3, 6, and 12 Months after Listing by Medical Urgency Status  
at Listing for Adult Registrations Added to the Heart Alone Waiting List during 2014-2016)**

Medical Urgency Status at Listing	Registrations Added	Months After Listing	Number Removed for Death	Death Rate	95% CI of Death Rate
Status 1A	2745	3	335	12.2%	[ 11.0%, 13.4%]
		6	395	14.4%	[ 13.1%, 15.7%]
		12	443	16.1%	[ 14.8%, 17.5%]
Status 1B	5092	3	228	4.48%	[ 3.94%, 5.07%]
		6	335	6.58%	[ 5.92%, 7.28%]
		12	452	8.88%	[ 8.12%, 9.68%]
Status 2	3255	3	146	4.49%	[ 3.81%, 5.23%]
		6	232	7.13%	[ 6.28%, 8.04%]
		12	332	10.2%	[ 9.20%, 11.3%]
All	11092	3	709	6.39%	[ 5.95%, 6.85%]
		6	962	8.67%	[ 8.16%, 9.20%]
		12	1227	11.1%	[ 10.5%, 11.7%]
Note: 1) Death rate was calculated using competing risk method. 2) Death included removal from the waiting list for being too sick.					

For the past several decades there has been scientific and clinical interest in the development of ex-vivo heart perfusion (EVHP) with oxygenated and nutrient enriched blood to reduce ischemic injury to the donor heart and potentially enable ex-vivo assessment of metabolic and mechanical function. More recently, EVHP has been used to potentially expand the donor pool to include hearts from donation after circulatory death (DCD).

Until recently, beating hearts from donation after brain death (DBD) donors were the only heart donors used for transplantation worldwide. DBD donors offer the advantage of permitting functional assessment before procurement, allowing for selection of only optimal donor hearts, and more importantly, organs are not subjected to the detrimental effect of warm ischemia in the donor prior to retrieval. The simple preservation method of cold storage became routinely used to transport DBD hearts between the donor and recipient hospitals and adequately preserves these ideal donor hearts. However, during the last 20 years, the number of suitable DBD donors has plateaued while the number of patients diagnosed with end stage organ failure continues to increase. As a result, the waiting list for organ transplantation has grown. To address the organ shortage, DCD donors are being increasingly used to procure donor lungs, livers, and kidneys (see [Figure 3](#) below).

**Figure 3: DCD Donors and DBD Donors in the U.S.**

However, due to potential damage of warm ischemia in the donor and the functional arrest of the heart that may never recover, DCD donors are **not** utilized for adult heart transplantation in the U.S. In contrast, international transplant centers have been successfully transplanting hearts from DCD donors, using the OCS Heart System for resuscitation, preservation and assessment of these hearts prior to transplantation. The OCS Heart System can minimize the detrimental effects of ischemia because it perfuses the donor heart with warm oxygenated blood. It enables the heart to be resuscitated to full beating state, and importantly enables the transplant team to assess metabolic (lactate production) and perfusion parameters of these hearts to determine their suitability for transplantation. These capabilities are critical when using extended criteria and DCD donor hearts to minimize the risks on the recipients receiving these organs.

Currently, the TransMedics' OCS Heart technology is the only portable system available for ex-vivo maintenance of the donor heart in a metabolically active and beating state.

Specifically, with regard to the challenges posed by DCD donor hearts noted above, the OCS Heart System offers the following advantages and capabilities:

- Resuscitation of the DCD heart into beating physiologic state ex-vivo to enable for the assessment of the donor heart's viability.
- Reduction of the time-dependent ischemic injury to the donor hearts during preservation, thus eliminating significant logistical and geographical barriers to heart transplantation that currently exist with cold storage preservation.
- Optimization of donor heart ex-vivo environment by optimizing oxygen and substrate delivery, while also replenishing key hormones and nutrients that are depleted due to the brain-dead condition in the body of the donor, which would negatively impact cardiac function if not replenished.
- Assessing the adequacy of the perfusion and metabolic condition of the donor heart utilizing standard lactate levels to allow physicians to judge the suitability of the organ for transplantation using the standard criteria that physicians currently use when harvesting

the organ from the donor, thus substantially minimizing the risk of transplanting poor hearts into recipients.

In summary, patients listed for heart transplantation due to their end stage heart disease are suffering from a terminal, life-threatening condition. Increasing the number of heart transplants by preserving extended criteria donors and DCD hearts with the OCS Heart System has the potential to provide patients with end stage heart failure with the gold-standard, life-saving treatment.

## **2. SUMMARY OF PRIOR TESTING AND INVESTIGATIONS**

### **2.1. OCS Heart Preclinical Testing**

The OCS Heart System is CE marked and has undergone extensive preclinical testing to demonstrate its safety, effectiveness, and readiness for clinical use. The Heart Perfusion Set has also been evaluated and tested in accordance with ISO-10993 “Biological Evaluation of Medical Devices,” including evaluations for acute toxicity, irritation, sensitization, cytotoxicity, hemolysis, genotoxicity and pyrogenicity. These test results demonstrated that the device and its materials are biocompatible and suitable for their intended use. The Heart Perfusion Set will be provided sterile using validated methods, and is appropriately packaged to maintain sterility. The OCS has also undergone extensive preclinical bench testing for: electrical safety; electromagnetic compatibility; and validation and verification testing (including validation of the device software). All tests and results have demonstrated that the OCS meets its expected performance specifications and is safe and suitable for clinical use.

### **2.2. Preclinical Animal Testing of OCS Heart System for DCD hearts**


Two preclinical animal studies have been published that evaluated the use of the OCS Heart System to preserve DCD hearts in animal models.

#### **2.2.1. Iyer, et al., 2015**

This study evaluated the use of the OCS Heart System to preserve DCD hearts in a porcine orthotopic heart transplant model. DCD hearts preserved with the OCS Heart System were compared to DCD hearts preserved using standard cold storage for 4 hours.

All donor hearts were exposed to 30 minutes of warm ischemia in a DCD asphyxia model prior to being flushed with cardioplegia. The comparison of the experimental timeline for the two groups is shown in [Figure 4](#) below. Orthotopic transplantation into recipient animals was then performed.

**Figure 4: Comparison of Experimental Timeline for OCS and Control Groups (Figure 1 from Iyer, et al., 2015)**



Five of six hearts preserved with the OCS heart system demonstrated favorable lactate profiles and all five could be weaned off cardiopulmonary bypass post-transplant compared to 0 of 3 hearts preserved with cold storage. The authors concluded that DCD hearts preserved with the OCS heart system demonstrated viability before and after transplant, and that human studies of DCD hearts using the OCS Heart System are warranted.

## 2.2.2. García Sáez, et al., 2015

This study evaluated the use of the OCS Heart System to preserve DCD hearts in an ex vivo porcine model. Circulatory death was induced in five pigs and the agonal time was calculated as the time between a reduction in blood pressure < 50 mm Hg or a fall in saturation below 70% and the cessation of electrical activity. After an additional 15 minutes of warm ischemia, hearts were procured and instrumented on the OCS and the procured grafts were assessed over a period of 4 hours. The results showed that four hearts were successfully resuscitated on the system with agonal times of 8, 15, 20 and 34 minutes. These grafts had good visual contractility and declining lactate and were considered transplantable. One graft, with agonal time = 34 minutes, had increased lactate and abnormal contractility and was not considered suitable for transplant. One heart with 48 minutes of agonal time could not be resuscitated. The authors compared the hemodynamic parameters during OCS perfusion and degree of edema after explantation with historical control grafts and no significant difference was found (Table 2).



**Table 2: Comparison of Hemodynamic Parameters for DCD Hearts Preserved on OCS and Historical Control (standard criteria hearts) preserved on OCS (Table 1 from García Sáez, et al., 2015)**

<b>Table – Comparison of hemodynamic parameters during OCS perfusion and degree of edema after explantation from the system between historical control grafts and grafts after cardiocirculatory death.</b>			
<b>Hemodynamic parameters</b>	<b>Control OCS</b>	<b>DCD hearts—OCS</b>	<b>P value</b>
Aortic pressure (mm Hg)	62 ± 11	54 ± 7	0.48
Coronary flow (mL/min)	670 ± 40	720 ± 30	0.29
Heart rate (bpm)	89 ± 9	88 ± 13	0.46
Weight gain %	33 ± 6	27 ± 5	0.40
Water content %	84.5 ± 1.6	84.1 ± 0.2	0.372

The authors concluded that the hearts from DCD donors can be successfully resuscitated on the OCS in a scenario that simulates clinical conditions.

### **2.3. OCS Heart Clinical Testing for DCD Hearts Outside the U.S.**

Due to the damage done by warm ischemia and the mechanical arrest in the donor, only DBD donors are currently utilized for adult heart transplantation in the U.S. In contrast, international transplant centers have been transplanting hearts from DCD donors, using the OCS Heart System for resuscitation, preservation and assessment of these hearts prior to transplantation. The OCS Heart System can minimize the detrimental effects of ischemia because it perfuses the donor heart with warm oxygenated blood. It enables the heart to be resuscitated to full beating state, and importantly enables the transplant team to assess metabolic (lactate production) and perfusion parameters of these hearts to determine if their suitability for transplantation. These capabilities are critical when using marginal/questionable and DCD donor hearts to minimize the risks on the recipients receiving these organs.

#### **2.3.1. Messer, et al., 2017**


Messer, et al. (2017) has published the results of a study of the OCS Heart System for preserving DCD donor hearts in the UK. This was a single-center observational matched cohort study comparing consecutive patients who received transplants of DCD donor hearts between February 1, 2015, and March 31, 2017, vs. matched recipients who received transplants of DBD donor hearts between February 1, 2013, and March 31, 2017. There was no difference in implant technique or immunosuppressive regimens during this period. DCD hearts were transported and continually perfused on the OCS Heart System. DBD hearts all underwent the current standard of direct procurement and cold storage until transplantation.

DCD heart donors were restricted to Maastricht category III donors, defined as expected death after the withdrawal of life- supportive therapy (WLST). A retrospective cohort of DBD heart transplants,

matched for donor and recipient characteristics, was used as a comparison group. The primary outcome measure of this study was 90-day survival. There were 26 DCD heart transplants performed during the 25-month study period. The use of the OCS Heart System resulted in an 86.7% rate of successful utilization of DCD hearts for transplantation. Survival at 90 days was not significantly different between DCD and matched DBD transplant recipients (DCD, 92%; DBD, 96%;  $p=1.0$ ). Hospital length of stay, treated rejection episodes, allograft function, and 1-year survival (DCD, 86%; DBD, 88%;  $p=0.98$ ) were comparable between groups.

Of the 26 DCD hearts transplanted, 12 used Normothermic Regional Perfusion (NRP) before OCS and 14 used Direct Procurement and Preservation (DPP). During the NRP procedure, following circulatory arrest the cerebral circulation was terminated but perfusion was restored to the thoracic and abdominal organs within the donor body. Functional assessments of the heart were performed after which donor blood was collected and the heart was arrested with cold cardioplegia. (NRP will not be used in this study). The DPP procedure followed the standard OCS blood collection and cardioplegic arrest of the donor heart. In the DPP arm, utilization was 77.8% (14/18) and 90-day survival was 86% (12/14).

**Figure 5: K-M Survival of Recipients of DCD and DBD Donors (Figure 2 from Messer, et al., 2017)**



The authors noted that DCD heart transplantation may increase heart transplants by 17% to 30%. During the study period, 84 DBD heart transplants were performed at this institution and the 26 additional DCD heart transplants increased the number of transplants by 33%. The authors concluded that the adoption of DCD heart transplantation can be safely implemented into widespread routine clinical practice.

### 2.3.2. Dhital, et al. (2015 and 2017)

The first report, published in 2015 in the Lancet, described transplantation of DCD hearts into three recipients (two men, one woman; mean age 52 years). They received Maastricht category III controlled hearts donated after circulatory death from people younger than 40 years and with a



maximum warm ischemic time of 30 min. Donor heart warm ischemic times were 28 min, 25 min, and 22 min, with OCS Heart perfusion times of 257 min, 260 min, and 245 min, respectively. Two patients needed temporary mechanical support. All three recipients had normal cardiac function within a week of transplantation, and, at the time of the report, were alive and recovering well at 176, 91, and 77 days after transplantation.

The second report, published in 2017, described the experience of using the OCS Heart System to preserve DCD hearts at St. Vincent's Hospital in Sydney, Australia. The donors were Maastricht Category III donors, < 40 years of age, no history of cardiac disease or cardiac risk factors, minimal inotropes and an expected warm ischemia time of 30 minutes. All donor hearts were perfused with the OCS Heart System. Time from withdrawal of therapy to cessation of circulation was 4 to 25 minutes (median 14 minutes). Total warm ischemic time was 14 to 28 minutes (median 25 minutes), with the time on OCS from 210 to 410 minutes (mean 302 minutes). Results for 12 patients have been reported. One patient needed mechanical support with IABP and 4 patients required ECMO support. There has been no mortality and all patients have normal biventricular function at 25 to 829 days post-transplant at the time of the report. The authors concluded that excellent graft and recipient survival can be achieved from transplantation with DCD hearts using the OCS Heart System.

### **2.3.3. García Sáez, et al. (2016, 2017)**

García Sáez, et al. (2016) reported on the outcomes of 2 recipients with long-term left ventricular assist device (LVAD) support who were successfully transplanted with DCD hearts preserved on the OCS Heart System despite the adverse donor/recipient risk profile. The authors noted "The ability to assess graft viability is of particular importance in DCD HTx, where, in contrast to the DBD setting, the donor organ has invariably been subjected to a sustained ischemic insult before procurement. We deliberately prolonged OCS support duration to allow comprehensive graft assessment and to achieve surgical preparedness in technically demanding recipients with LVADs in situ." In this report, the two patients were alive and well 290 and 291 days after transplantation.


This same author followed up with a report of 5 high-risk recipients (García Sáez, et al., 2017). This included three recipients with LVADs and one subject who was undergoing a second heart transplantation. All patients received DCD heart transplants preserved on OCS. Following transplant, two patients developed primary graft dysfunction requiring mechanical support. One patient died within the first 30 days post-transplant (the patient who had undergone a second heart transplant). The remaining 4 patients are well and alive at a mean 324 days post-transplant (range 18-496 days).

### **2.3.4. Chew, et al. (2019)**

Chew, et al. reported on experience of 23 DCD heart transplants from 45 DCD donor referrals that were transplanted between July 2014 and April 2018 at St. Vincent's Hospital, Sydney, Australia. Hearts were retrieved from 33 of 45 DCD donors. A total of 12 donors did not progress to circulatory arrest within the pre-specified timeframe. Eight (8) hearts failed to meet viability criteria during normothermic machine perfusion, and 2 hearts were declined due to machine malfunction, leading to 23 DCD heart transplants. All recipients had successful implantation, with mechanical circulatory support utilized in 9 cases. One case requiring extracorporeal membrane oxygenation subsequently died on the sixth post-operative day, representing a mortality of 4.4% over 4 years with a total follow-up period of 15,500 days for the entire cohort. All surviving recipients had normal cardiac function on

echocardiogram and no evidence of acute rejection on discharge. All surviving patients remain in New York Heart Association functional class I with normal biventricular function.

**Figure 6: Recipient Survival after DCD and DBD Heart Transplantation (Chew, et al., 2019)**



#### 2.4. Additional Clinical Studies of the OCS Heart System for Standard and Extended Criteria and DCD Donor Hearts

TransMedics has conducted two previous IDE studies of the OCS Heart System in Standard Criteria and Extended Criteria Donor Hearts, and one IDE study is currently ongoing using the OCS Heart System for DCD Donor Hearts. These studies provide supporting evidence for the safety of the OCS Heart System for this investigation and are briefly described below.

- The OCS Heart EXPAND trial was a prospective, single arm study of 75 heart transplant recipients who received hearts preserved on the OCS. These hearts were from extended criteria donors, i.e., those that are seldom transplanted in transplant institutions today without the OCS. The results demonstrated:
  - Utilization rate of 80.6% of donor hearts that are rarely used for transplantation today. These donor hearts were refused by other (non-EXPAND) centers an average of 66 times but were able to be preserved and 81% were transplanted successfully in this study.
  - The incidence of ISHLT severe PGD was 10.7%, and the incidence of ISHLT moderate or severe PGD was 14.7%. These rates compare favorably with contemporary literature reporting PGD rates post-heart transplantation using the ISHLT criteria.
  - Survival at 30 days, 6 months, and 12 months was 95%, 88%, and 84%, respectively.

- The FDA also approved a Continued Access Protocol (CAP) for EXPAND called the EXPAND CAP. The study is on-going and data are still being collected, but based on the available data the results show:
  - 45 donor hearts were preserved and assessed on the OCS Heart System.
  - The utilization rate is 91.1%, with 41 of 45 extended criteria donor hearts successfully transplanted.
  - The 41 transplanted patients have reached a minimum of 30-day follow-up and all survived (100% survival at 30-days). Twenty-six (26) patients have reached 6 months post-transplant and these patients experienced 100% graft and patient survival.
  - The incidence of ISHLT severe heart PGD was 2.1% , and the incidence of ISHLT moderate or severe PGD was 17.1%
- PROCEED II was the first pivotal study of the OCS Heart System. It was a randomized study of the OCS Heart System compared to standard of care cold storage, and it enrolled standard criteria donor hearts. The study met its primary endpoint and non-inferiority was shown in 30-day survival, as well as in the secondary endpoint, i.e., cardiac graft-related SAEs. Longer-term data, obtained from the SRTR database, showed lower survival rates for the OCS group at 2-3 years of follow-up; however, the incidence of cardiac graft-related deaths was similar and other deaths were typical for heart transplant recipients (late infection, malignancy, multi-organ failure). The results of this study were published in the Lancet (Ardehali, et al., 2015).
- Studies of the OCS Heart System for preservation of standard criteria donor hearts conducted outside the U.S. at hospitals in Germany and the UK showed improved rates of survival and lower rates of PGD for OCS compared to standard of care cold storage (Koerner, et al., 2014).
- The OCS DCD Heart trial is an IDE trial that is currently being conducted by TransMedics in the U.S. In this trial 90 patients were to be transplanted with DCD hearts preserved on the OCS Heart System and up to 90 patients were to be transplanted with standard of care hearts that were preserved on cold storage. The study is still ongoing; the patients are still being followed in the study and the 6 month primary endpoint data has not yet been analyzed. The OCS DCD Heart study data has been reviewed by an independent Data Safety Monitoring Board (DSMB) and no study concerns have been identified. Preliminary and available data show:
  - 84 DCD donor hearts were preserved and assessed on the OCS Heart System.
  - The donor heart utilization rate as defined in the study protocol is 91.1%.
  - 43 transplanted patients have reached a minimum of 30-day follow-up and all patients and grafts survived (100% survival at 30-days).
  - The incidence of ISHLT defined severe heart PGD was 14%, and the incidence of HGRSAE (moderate or severe PGD) was 16.3%. There have been no primary graft failures.

## 2.5. Overall Summary of Clinical Data to Support OCS DCD Heart CAP

In summary, studies of the OCS Heart System for the preservation of DCD hearts have been performed outside of the U.S. These studies have shown 77.8 - 86.7% utilization rate, with 90-day and 1-year survival comparable to outcomes obtained with standard criteria donor hearts preserved using cold storage standard of care. TransMedics is currently conducting the OCS DCD Heart trial. The preliminary data are encouraging and show a utilization rate of 91.1% and 30-day patient survival of 100% in the 43 patients who have reached this follow-up.

In addition, the OCS Heart EXPAND trial, the OCS Heart EXPAND CAP and studies of the use of OCS to preserve extended criteria hearts performed outside the U.S. shows high utilization rate, with good clinical outcomes, demonstrating the ability of the OCS Heart System to expand the potential pool of donor organs. These data provide strong support for the OCS DCD Heart CAP.


## 3. DEVICE DESCRIPTION

The OCS Heart System is an integrated portable platform designed to maintain donor hearts in a near physiologic, normothermic perfusion state. The OCS Heart System consists of:

- OCS Heart Console
- OCS Heart Perfusion Set – comprised of Heart Perfusion Module (HPM) and Accessories
- OCS Heart Solution Set

These major components are shown in [Figure 7](#) below.

**Figure 7: Figures of the OCS Heart System**



### 3.1. Description of Major Components

#### 3.1.1. OCS Heart Console

The OCS Heart Console is the reusable, non-sterile portable enclosure incorporating the electronics, software, fluid pumping systems, monitoring systems, power supply, batteries, gas cylinder, mobile

base and Wireless Monitor. The Wireless Monitor displays information and allows the user to adjust certain settings.

The OCS Heart Console provides a rigid compartment to house and securely connect to the HPM during transport. The OCS Heart Console connects to a mobile base with locking wheels.

### **3.1.2. Heart Perfusion Set (HPS)**

The Heart Perfusion Set (HPS) consists of the Heart Perfusion Module (HPM) and Disposable Accessories. The HPM provides a closed circulatory system to protect, maintain and support the heart. It uses a physical conduit to connect to the heart, incorporates various sensors, and interfaces with the OCS Heart Console to oxygenate, warm and circulate the perfusate.

The accessories are intended to:

- Collect and process the donor blood
- Prime and then infuse the OCS Heart Solution to the HPM
- Connect the heart to the HPM circuit
- Facilitate monitoring of the heart operation
- Infuse cardioplegia to terminate the preservation.

The HPM provides the sterile blood circuit and protected environment for a heart within the OCS. It is designed as a single-use, pre-assembled module that mounts into the OCS. The heart is instrumented within the heart chamber of the HPM. The Wireless Monitor displays measurements made within the HPM. The HPM includes:

- Dual lid heart-specific heart chamber
- Integrated and easily accessible blood sampling and de-airing manifold
- Integrated pulsatile pump head interface
- Integrated low shear titanium blood warmer
- Integrated blood oxygenator (or gas exchanger)
- Integrated sensors (pressure and temperature) and circuitry to communicate with the Console.

### **3.1.3. OCS Heart Solution Set**


The OCS Heart Solution Set consists of two proprietary heart preservation solutions, a Priming Solution and a Maintenance Solution, to replenish the nutrients and hormones (adenosine) that the metabolically active donor heart requires. The solutions are packaged in a three-chamber bag (nominal volume of 500 ml per chamber). At the time of use, the Priming Solution (500 ml) is dispensed into the HPM. The Maintenance Solution is manufactured as two component solutions (500 ml each) that are individually manufactured and then mixed immediately before infusion into the HPM. Additives are required at the time of use. The additives are not supplied by TransMedics, and are added by user.

The OCS Heart Solution Set is not intended to be administered directly to the donor or the recipient. The donor heart is arrested prior to removal using a standard cardioplegia solution. Prior to transplantation into the recipient, the donor heart is arrested on the OCS through the use of a standard cardioplegia solution, at which time the perfusate (including the donor blood, Priming Solution and Maintenance Solution) are flushed from the donor heart.

### 3.1.4. Mode of Action - Overview

The OCS Heart System preserves the heart in a near-physiological, beating state by perfusing the heart with a warmed, donor-blood based perfusate that is supplemented with nutrients and oxygen in a controlled and protected environment referred to as the circuit. The circuit is illustrated in [Figure 8](#) below. The OCS contains a pulsatile pump that directs flow through the gas exchanger, to be oxygenated, and then through the blood warmer and then to the aorta of the donor heart. An additional perfusate component, known as the TransMedics Maintenance Solution, is infused into this circuit. The heart consumes oxygen and nutrients as the blood travels from the aorta through the coronary arteries and returns blood to the circuit through its pulmonary artery. The OCS maintains the blood at a constant temperature, oxygenates the perfusate at a constant rate, and provides perfusate in a pulsatile flow at a constant rate.

**Figure 8: Schematic of the OCS Heart System Fluid Flow**



## **4. TRIAL OBJECTIVES**

The objective of the OCS DCD Heart CAP is to enable continued clinical access to DCD heart transplantation in the U.S. and to continue to collect additional data on the performance of the OCS Heart System to resuscitate, preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation.

### **4.1. Trial Design**

This is a prospective, single arm, continued access protocol (CAP).

### **4.2. Trial Size and Subject Follow-up**

A maximum of 25 participating sites and up to 90 transplanted DCD heart recipients will participate.

Subjects will be followed for 12 months from the date of transplantation (some of which may be post-market). Data from UNOS/OPTN transplantation database will be obtained through 5 years after transplant. The follow-up assessments are summarized in [Appendix 2](#).

## **5. TRIAL ENDPOINTS**

### **5.1. Primary Endpoint**

The primary endpoint is patient survival at 6 months post-transplant.

### **5.2. Secondary Endpoint**

Utilization Rate is defined as the number of eligible DCD donor hearts that met the warm ischemic time limit and were instrumented on the OCS Heart System that meet the acceptance criteria for transplantation after OCS Heart preservation divided by the total number of eligible DCD donor hearts that met the warm ischemic time limit above and were instrumented on the OCS Heart System.

### **5.3. Safety Endpoint**

The safety endpoint is defined as the incidence of Heart Graft-related Serious Adverse Events (HGRSAEs) in the first 30 days post-heart transplantation in the DCD Heart Transplanted Recipient Population, defined as the following adverse events (at most one per type):

- Moderate or Severe heart PGD (left or right ventricle) (not including rejection or cardiac tamponade) according to ISHLT consensus manuscript (as defined in [Appendix 1](#) of this protocol).
- Primary graft failure requiring retransplantation.

### **5.4. Other Endpoints**

Other endpoints include:

- Patient and graft survival at 30 days post-transplant
- Patient and graft survival at 30 days or initial hospital discharge, if later than 30 days

- Severe PGD (left or right ventricle) (not including rejection or cardiac tamponade) according to ISHLT consensus manuscript (as defined in [Appendix 1](#) of this protocol)
- Use of post-transplant mechanical circulatory support (LVAD, RVAD, BiVAD) for > 72 hours immediately post-transplant.
- Patient survival at 1 year after transplant.

## **6. TRIAL POPULATION**

The trial will include primary heart transplant recipients. Medicare beneficiaries with a clinical need for transplantation will be treated in the same manner as patients not covered by a Medicare plan. The rules of participation and results of the study apply to Medicare and non-Medicare covered patients in the same manner.

### **6.1. DCD Donor Eligibility Criteria**

#### **Donor Inclusion Criteria**

- Maastricht Category III DCD donor, defined as expected death after the withdrawal of life-supportive therapy (WLST)
- Donor age 18-49 years old inclusive
- Warm ischemic time (WIT)  $\leq$  30 mins, with warm ischemic time defined as: Time from when mean systolic blood pressure (SBP) is < 50 mmHg or peripheral saturation < 70% to aortic cross-clamp and administration of cold cardioplegia in the donor.

#### **Donor Exclusion Criteria**

Donor hearts will be excluded if they meet any of the following criteria:

- Previous cardiac surgery;
- Known coronary artery disease;
- Cardiogenic shock or myocardial infarction;
- Sustained terminal EF of  $\leq$  50%; or
- Significant valve disease except for competent bicuspid aortic valve.

### **6.2. Recipient Eligibility Criteria**

#### **Recipient Inclusion Criteria**

- Primary heart transplant candidates
- Age  $\geq$  18 years old
- Signed: (1) written informed consent document; (2) authorization to use and disclose protected health information; and (3) consent to TransMedics' use of recipients' UNOS/OPTN data and consent to TransMedics' use of recipients' INTERMACS data.

#### **Recipient Exclusion Criteria**

- Prior solid organ or bone marrow transplant



- Chronic use of hemodialysis or diagnosis of chronic renal insufficiency
- Multi-organ transplant.

### 6.3. DCD Heart Subject Enrollment and Screen Failures

As part of the screening process for subjects in the OCS DCD CAP, the following must occur:

- Recipient must be matched with a DCD donor heart that meets eligibility criteria;
- Recipient must meet eligibility criteria;
- The matched DCD donor heart must be accepted for transplantation in the donor chest by the transplant surgeon or designee (including meeting the Warm Ischemic Time limit outlined in this protocol);
- The matched donor heart must be instrumented on the OCS;
- The donor heart matched to this recipient must meet transplantability criteria per Section 7.4.1 of the protocol following OCS Heart System instrumentation; and
- The recipient must be transplanted with the DCD heart instrumented on OCS.

A subject will be considered a screen failure under any of the following conditions:

- The matched DCD donor heart is not accepted for transplantation in the donor chest by the transplant surgeon or designee (including meeting the Warm Ischemic Time limit outlined in this protocol).
- The matched DCD donor heart is not instrumented on the OCS.
- The donor heart matched to this recipient fails to meet transplantability criteria per [Section 7.4.1](#) of the protocol following OCS Heart System instrumentation (i.e., donor heart turndown).
- The recipient fails to meet inclusion/exclusion criteria on the day of the potential transplant after an eligible DCD donor heart is instrumented on the OCS Heart System and accepted for transplantation following OCS preservation.
- Logistical reasons prevent transplantation of DCD donor heart instrumented on the OCS Heart System that meets acceptance criteria for transplant following OCS preservation (e.g., transplant center or OPO issues, transportation or allocation issues, surgeons or ORs are unavailable).

**A subject will be considered enrolled in the study when the subject is transplanted with the OCS-instrumented organ. Trial data will be collected only for those subjects considered enrolled in the trial.**

Subjects who are screen failures that remain eligible for the study will return to the waiting list for another heart transplant. Depending on the donor match, this next transplant may be either in the OCS DCD Heart CAP or the subject may be transplanted using standard cold storage and will not be enrolled in this study.

## **7. PRE-OPERATIVE TRIAL PROCEDURES**

### **7.1. Subject Identification**

Those patients who initially appear eligible for the trial will have the trial explained to them, be invited to participate, and will be asked to sign an informed consent. When a matching eligible DCD donor heart becomes available, the inclusion and exclusion criteria for the recipient will be re-verified. If the recipient is no longer eligible for the trial, they will be considered a screen failure and they will exit the study, and no information will be collected for these subjects.

### **7.2. Recipient Day of Transplant Assessment**

The purpose is to conduct a final assessment of whether the potential recipient still meets the eligibility criteria. Specific data to be collected can be found in the Schedule of Assessments in [Appendix 2](#).

### **7.3. Donor Screening and Acceptance for DCD Hearts**

The investigator or a member of her/his transplant team will evaluate the donor and the quality and suitability of the DCD heart for: (1) transplantation, according to his or her clinical judgement and (2) eligibility for the DCD Heart arm of this study, including meeting the warm ischemic time limit outlined in this protocol. If the donor heart does not meet the above criteria, it will be considered a “dry run” and no information on this donor heart will be collected.

If the donor heart meets the above criteria and is preserved on OCS, baseline characteristics, demographics and other donor information will be collected at this visit. Parameters to be collected can be found in the Schedule of Assessments in [Appendix 2](#).

### **7.4. DCD Donor Heart Retrieval and OCS Preservation and Assessment**

Upon acceptance into the trial, the investigators will retrieve and preserve the donor heart according to the OCS Heart Instructions for Use (IFU).

#### **7.4.1. Donor Heart Acceptance/Rejection for Transplantation after OCS Preservation**

Donor hearts preserved on the OCS should have stable parameters throughout perfusion after initial stabilization period (defined as the time period during which perfusion is initiated and primary parameter adjustments are made).

#### **Accept for Transplantation**

Donor hearts preserved on the OCS Heart System to be maintained within the following target ranges:

- Stable or downward trending lactate after initial adjustments of the OCS Heart perfusion parameters to achieve adequate perfusion to the donor heart
- Stability of OCS Heart Perfusion Parameters within range:
  - AOP 40-100 mmHg.
- Transplanting surgeon and/or heart failure cardiologist must clinically accept the OCS perfused donor heart for transplantation.

**Reject for Transplantation**

- Transplanting surgeon and/or heart failure cardiologist clinically unsatisfied with donor heart condition/performance on the OCS Heart System at final evaluation.
- Unstable and rising arterial lactate despite maneuvers to optimize perfusion parameters.

Note: certain donor hearts may require perfusion with parameters outside of these guidance ranges. Acceptance for transplantation should be primarily based on an acceptable lactate trend.

Any decision to turndown hearts after preservation and assessment on OCS Heart System should be documented on the appropriate CRF. The turndown heart should be sent to the central core lab for assessment of any inherent cardiac pathology that was not diagnosed at retrieval of the donor heart.

**8. TRANSPLANT, IMMEDIATE POST-OPERATIVE AND LONG-TERM FOLLOW-UP****8.1. Transplant Details**

The following information concerning the transplant procedure will be collected:

- The organ recipient unique post-transplant patient identifier
- Warm ischemic time as defined in this protocol
- Total cross clamp duration in minutes (from donor cross-clamp application to removal of cross-clamp in the recipient)
- Pre-OCS cold ischemia time (time from donor cross clamp until start of perfusion on OCS)
- Post-OCS cold ischemia time (time from heart flush on OCS until aortic cross-clamp removal in the recipient)
- Any surgical complications encountered during surgery.

**8.2. Post-transplant Functional Assessments Day 0 – Day 30**

- Heart PGD Surveillance in the first 24 hours
- Initial use of Mechanical Circulatory Support in the first 72 hours
- Inotropic Support for first 24 hours from T0 to T24 hours after ICU admission
- Echocardiogram results within the first 24 hours post-transplant (if available) starting from ICU admission
- Right Heart Catheter Data (not required; data collected only if performed as part of institution's standard of care)
- Initial Post-Transplant ICU Stay
- Initial Post-Transplant Hospital Stay
- Patient and Graft Survival at Day 30 will be assessed.
- Serious Adverse Events: All SAEs will be collected for the first 30 days post-transplant. SAEs will be followed until the investigator designates the event to be either resolved or its effect on the patient's condition stabilized.

### **8.3. Long-term Follow-up: 6 and 12 Months**

Follow-up data collection will be conducted at 6 months ( $\pm$  30 days) and 12 months ( $\pm$  60 days) post-transplant to evaluate patient survival, graft survival and diagnosis of cardiac allograft vasculopathy. These follow-ups may be performed by phone.

### **8.4. Evaluation of Adverse Events**

Only serious adverse events (SAEs) and Heart Graft-Related SAEs (HGRSAEs) will be captured in this study.

#### **8.4.1. Serious Adverse Events (SAEs)**

Serious adverse events will be collected only through Day 30 post-transplant. An adverse event will be classified as serious if it meets any of the following criteria:

- Results in, leads to, or contributes to, a death
- Is life-threatening
- Results in permanent disability or incapacity (i.e., permanent impairment of a body function or permanent damage to a body structure)
- Requires in-patient hospitalization or prolongs hospitalization
- Necessitates medical or surgical intervention to preclude a permanent disability or incapacity
- Results in fetal distress, fetal death or a congenital anomaly/birth defect.

#### **8.4.2. Heart Graft-Related SAEs (HGRSAEs)**

Heart Graft-related SAEs (HGRSAEs) are defined as:

- Moderate or Severe heart PGD (left or right ventricle) (not including rejection or cardiac tamponade) according to ISHLT consensus manuscript as defined in [Appendix 1](#) of this protocol.
- Primary graft failure requiring re-transplantation.

HGRSAEs will be collected from the time a subject is transplanted with the OCS DCD Heart until the completion of the 30-day follow-up evaluation. A HGRSAE will be followed until resolution or stabilization of the event.

#### **8.4.3. Unanticipated Adverse Device Effect (UADE)**

The investigator will assess each serious adverse event for whether it is anticipated or unanticipated using the list specified in [Section 8.4.4](#) below.

An UADE means any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously identified or encountered before at least once in standard clinical practice, in nature, severity, or degree of incidence in the investigational plan or application (including a supplementary plan or

application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects.

#### 8.4.4. Anticipated SAEs

Anticipated SAEs that are associated with heart transplant procedures within the first 30 days after heart transplant includes, but is not limited to:

- Acute rejection
- Atrial and ventricular arrhythmias
- Bleeding (major)
- Hemodynamic instability
- Death
- Fever
- Infection
- Primary Graft Dysfunction
- Respiratory failure
- Graft failure
- Sepsis
- Renal dysfunction
- Hyperammonaemia
- Malignancy (post-transplant lymphoproliferative disorder (PTLD))
- Multiple organ failure
- Myocardial infarction
- Neurological dysfunction
- Hepatic dysfunction
- Diabetes due to steroid and anti-rejection medications
- Gall stones
- GI bleeding
- Pancreatitis
- Peptic ulceration
- Gastritis
- Gastro esophageal reflux disease (GERD)
- Pneumo-mediastinum
- Pneumothorax
- Hemothorax
- Pleural bleeding
- Pleural effusion
- Venous thromboembolism (deep venous thrombosis [DVT])
- Pulmonary embolism (PE)
- Sternal wound dehiscence
- Organ deemed not transplantable after retrieval
- Stroke
- Psychosis
- Cerebrovascular accident
- Peripheral vascular clotting or occlusion due to insertion of mechanical support
- Limb gangrene due to vascular occlusion due to insertion of mechanical support
- Use of mechanical circulatory support
- Coagulopathy
- Hyperacute rejection
- Anastomotic site complications; narrowing, bleeding or occlusion
- Delayed sternal wound closure due to compromised cardiac function or excessive bleeding or both
- Bowel thromboembolic complications and gangrene

- Aspiration
- Cardiac tamponade
- Protamine and other anti-heparin medication reaction
- Heparin induced thrombocytopenia

#### 8.4.5. Reporting of Adverse Events

Unanticipated adverse device effects (UADE) should be reported to TransMedics, Inc., within 48 hours of the time the investigator learns of the event, but in no case later than 5 working days after learning of the event.

All SAE information will only be collected from transplant through day 30. SAEs should be entered into the study database as soon as possible. SAE will be followed until the investigator designates the event to be either resolved or its effect on the patient's condition stabilized. Details related to treatment of the SAE will also be collected.

#### 8.4.6. Relationship of an SAE or HGRSAE to OCS Heart System

The investigator will assess the relationship of the HGRSAE to the OCS Heart System. The relationship will be assessed using the following categories:

- **Definitely Related:** There is a reasonable causal and temporal relationship between preservation with the OCS Heart and the adverse event.
- **Possibly Related:** There is a reasonable relationship with preservation with the OCS Heart and the adverse event, but the causal relationship is unclear or lacking.
- **Unlikely Related:** There is a temporal relationship with preservation with the OCS Heart and the adverse event, but there is not a reasonable causal relationship between the OCS Heart and the event.
- **Unrelated:** There is no relationship between preservation with the OCS Heart and the adverse event.

#### 8.4.7. Severity

The investigator will rate the severity of the serious adverse event using the following categories:

- **Mild:** The adverse event is transient and/or easily tolerated by the subject.
- **Moderate:** The adverse event causes the subject discomfort and interrupts the subject's usual activities.
- **Severe:** The adverse event causes considerable interference with the subject's usual activities.

#### 8.4.8. Pre-Existing Conditions

Pre-existing diseases or conditions will not be reported as adverse events.

## 9. OCS HEART TRAINING RUNS

If not completed previously, prior to transplanting any DCD hearts in this study, all investigators will complete one or two training runs. The purpose of these training runs is to allow the investigator and the surgical team to become familiar with the procurement of DCD hearts, specifically, the warm ischemia inclusion criteria, and to obtain experience in instrumenting and resuscitating DCD hearts on the OCS Heart System. The donor organs procured and instrumented in the training runs are not intended for transplantation. The results of the training runs will not be included in any data analyses, including the calculation of the utilization rate.

## 10. STATISTICAL METHODS

### 10.1. General

Continuous variables will be summarized using descriptive statistics, specifically the mean, median, standard deviation, minimum, and maximum. Categorical variables will be summarized using frequencies and percentages.

### 10.2. Analysis Populations

#### 10.2.1. DCD Heart Transplanted Recipient Population

The ***DCD Heart Transplanted Recipient Population*** will consist of all eligible recipients who are transplanted with an eligible DCD donor heart that met the warm ischemic time limit defined above, preserved on OCS and met the transplantability criteria. The analyses of all effectiveness and safety endpoints, except the utilization rate, will be based on the DCD Heart Transplanted Recipient Population.

#### 10.2.2. OCS Heart Population

***The OCS Heart Population*** will consist of all eligible donor hearts that met the warm ischemic time limit above and were instrumented on the OCS Heart System. The analysis of utilization rate will be based on the OCS Heart population.

#### 10.2.3. Modified Intend-to-Treat (mITT) Population

The modified intend-to-treat (mITT) population will consist of all recipients who are transplanted according to this protocol. The mITT analysis will be considered secondary analyses of all effectiveness and safety endpoints.

### 10.3. Statistical Analysis

#### 10.3.1. Primary Endpoint

The primary endpoint is the patient survival at 6 months post-transplant.

The primary endpoint will be summarized using counts and percentages and an exact 95% confidence interval for the true percentage based on the binomial distribution.

### 10.3.2. Secondary and Other Endpoints

#### Secondary Endpoint:

Utilization Rate, defined in [Section 5.2](#).

The rate of donor hearts that were successfully transplanted after preservation and assessment on the OCS Heart System (i.e., donor heart utilization) will be summarized using counts and percentages and an exact 95% confidence interval for the true percentage based on the binomial distribution.

#### Other Endpoints:

- Patient and graft survival at 30 days post-transplant
- Patient and graft survival at 30 days post-transplant or at initial hospital discharge, if later than 30 days
- Severe heart PGD (left or right ventricle) (not including rejection or cardiac tamponade) according to ISHLT consensus manuscript (as defined in [Appendix 1](#))
- Use of post-transplant mechanical circulatory support (LVAD, RVAD, BiVAD) for > 72 hours immediately post-transplant.
- Patient survival at 1 year after transplant

Each endpoint will be summarized using counts and percentages and an exact (Clopper-Pearson) 95% confidence interval for the true percentage based on the binomial distribution.

### 10.4. Safety

Serious Adverse Events (SAEs) and Heart Graft-related Serious Adverse Events (HGRSAEs) will be collected within the first 30 days post-transplant and the mean number of HGRSAEs per subject will be summarized using descriptive statistics. HGRSAEs are defined as the following adverse events (at most one per type): Moderate or Severe heart PGD (left or right ventricle) (not including rejection or cardiac tamponade) according to ISHLT consensus manuscript (as defined in [Appendix 1](#)) and primary graft failure requiring retransplantation.

This endpoint will be summarized using descriptive statistics, specifically the mean, median, standard deviation, minimum, maximum, and a 95% confidence interval of the mean based on the t-distribution.

SAEs and HGRSAEs will also be tabulated using counts and percentages alone and in regards to the relationship of the HGRSAE to the device, and the severity of the HGRSAE.

### 10.5. Sample Size Determination

This is a continued access protocol and the sample size was not determined using statistical methods.

## 11. RISK ANALYSIS

This clinical trial has been designed to ensure that the benefits and knowledge gained from the trial outweigh the potential risks to the subjects.



### 11.1. Potential Risks

The potential risks to subjects from participation in this clinical trial include the following:

- **Potential Risks Associated with Heart Transplant Procedures:** These risks include post-operative complications not associated with the OCS Heart System such as graft failure, primary graft dysfunction, rejection, infection and other organs/systems complications, graft vessel disease (an expression of chronic rejection), abnormal kidney function, diabetes, high level of cholesterol, high blood pressure, cancer and neurological complications.
- **The Potential Risks Associated with OCS Heart System:** Subjects have the risk of not receiving organs preserved with the OCS Heart System under certain conditions including: (1) the OCS Heart System may not work properly, or there may not be personnel available trained in the use of the Heart System or (2) the OCS Heart System may malfunction, or the medical staff may make an error which could lead to damage of the donor heart. If this occurs, the subject will have to wait for a new donor heart to become available. As with any medical device, there is always a risk of extremely rare or previously unknown side effects developing from the treatment.
- **Potential Risk of Using a Donor Heart that is Unsuitable for Transplantation:** Regardless of the preservation system that is used, there is the risk that a patient can receive a heart that does not adequately function. This trial is designed to utilize hearts that would not be accepted for transplantation using cold storage preservation. There is the possibility that using such hearts may increase the risk of transplanting a heart that does not function appropriately. It is also possible that the donor heart may not meet transplantability criteria after OCS preservation and would be turned down for transplant. In the EXPAND trial and in trials of DCD donors conducted outside the U.S., only 20% of the donor hearts were turned down following OCS preservation so the anticipated frequency of this event is low.

### 11.2. Manner in Which the Potential Risks Have Been Minimized

The Sponsor has relied upon a number of different means, including the device design, risk analysis and management process, preclinical testing, and the clinical protocol itself, to minimize the risks to subjects and to protect their safety and welfare.

The OCS Heart System has undergone extensive preclinical and animal studies to demonstrate that the device performs as intended and all materials are biocompatible. Previous clinical studies, including the OCS Heart EXPAND trial and studies of DCD hearts performed outside the U.S., have not indicated any safety signals that would preclude initiation of this study.

In addition, this clinical protocol incorporates several procedures to minimize the risks to subjects and to ensure the benefits of the clinical trial outweigh its potential risks.

- The donor heart acceptance criteria after OCS Heart perfusion and assessment are based on clinically relevant markers for perfusion of donor hearts on OCS and clinical standards of accepting conventional donor hearts for transplantation. Thus, the donor heart will be fully assessed based on the current standards of evaluating donor hearts before accepted for transplantation. The recipient should not be subjected to any surgical or medical

procedures until the heart has been accepted for transplantation by the transplanting team.

- As with any heart transplant procedure, subjects will be monitored before, during and after the operative procedure. The investigators have extensive experience with heart transplants and will be trained to use the OCS Heart System to further minimize risk.
- The trial will be monitored to ensure the identification, documentation, and analysis of adverse events; and to ensure compliance with the protocol and procedures that are in place for conducting research to protect the safety and well-being of all subjects.

### **11.3. Potential Benefits**

The low utilization of donor hearts has led to a severe shortage of donor hearts to meet the large and growing need for heart transplantation; the Scientific Registry for Transplant Recipients (SRTR) and Organ Procurement Transplant Network (OPTN) report that approximately 25% of the patients on the national waiting list have either died or their health deteriorated prior to a heart transplant procedure.

The OCS Heart System's preservation and assessment capabilities could potentially increase the rate of utilization of donor hearts that are not used due to the limitations of cold storage techniques. The previous Heart EXPAND study demonstrated an 80% utilization of extended criteria donor hearts, and studies of the OCS performed outside the U.S. observed 78 - 80% utilization of DCD hearts. This could improve the chances of waiting list recipients to receive a lifesaving heart transplant and reduce waiting list time and mortality. In addition, the OCS Heart System's ability to assess donor hearts after removal allows for the assessment of the function of the donor heart before it is transplanted.

### **11.4. Risks Benefit Ratio**

Based on the above, the benefits of using OCS Heart technology to recruit, preserve and assess donor hearts to ensure their suitability for heart transplantation outweigh the potential risks to trial subjects.

## **12. DEVICE/SITE MANAGEMENT**

### **12.1. Packaging and Labeling**

The OCS Heart Perfusion Set and accessories and the Perfusion Solution will be supplied sterile and are intended and labeled for single use only.

The OCS and its components will be clearly labeled as an investigational device according to 21 CFR 812.5. The labeling provides instructions for use for the device. A copy of the Instructions for Use will be provided to each investigational site.

### **12.2. Storage**

The investigational devices will be stored in a secure location. Access should be strictly limited to the investigators and their designees. Neither the investigators nor any designees may provide the investigational device to any subject not participating in this trial. The OCS Heart Perfusion Set should be stored at temperatures between -20°C and 50°C, and ambient humidity from 10-95%, no condensing.

*Note: The OCS Heart Perfusion Set should be operated at ambient temperatures (10°C to 35°C), and ambient humidity (20%-90%).*

### **12.3. Accountability**

The investigator or designee will maintain a record of investigational devices received, used, discarded, or returned to the Sponsor.

### **12.4. Device Complaints and Malfunctions**

The investigator will inform the Sponsor of any complaints or malfunctions during the course of the trial. The Sponsor will investigate all device complaints and malfunctions.

## **13. REGULATORY/ETHICS**

This clinical trial will be conducted in accordance with the requirements of the FDA Investigational Device Exemptions regulation (21 CFR Part 812), ISO Standard 14155, and in accordance with good clinical practices.

### **13.1. Institutional Review Boards (IRB)**

Prior to initiation of any trial procedures, trial documents will be submitted to each site's IRB for review and approval. In addition, any amendments to the protocol or informed consent form will be reviewed and approved (if necessary) by the IRB. The Sponsor must receive a letter documenting the IRB's approval at the clinical site prior to the initiation of the trial at that particular site.

### **13.2. Informed Consent**

The IRB approved written informed consent form will be signed and dated by the subject and the individual obtaining the consent. The subject will be given a copy of the signed informed consent form. The original will be kept in the patient's file by the investigator.

A copy of the proposed draft Informed Consent template is included in [Appendix 3](#).

## **14. DATA COLLECTION/RECORDS/REPORTS**

### **14.1. Investigator Records**

Prior to participation in the investigation, the investigators will provide the following documentation to the Sponsor:

- Signed Investigator Agreement
- Signed financial disclosure form
- Curriculum Vitae (CV).

Written approval of the protocol and informed consent document from the IRB; Investigators will be responsible to maintain on file the following records (Note that this is not the complete list of items to be maintained):

- All relevant correspondences and required reports that pertain to the trial
- Records of receipt, use or disposition of the investigational device

- Records of each subject's case history and exposure to the device
- Signed and dated consent forms
- Relevant observations, including records concerning adverse events, condition of each subject upon entering and results of diagnostic tests
- Protocol, and any amendments
- Subject recruiting materials
- Investigator curricula vitae.

The investigator will not dispose of any records relevant to this trial without: (1) written permission from the Sponsor and (2) providing an opportunity for the Sponsor to collect such records. The investigator will take responsibility for maintaining adequate and accurate electronic or hard copy source documents of all observations and data generated during this trial. Such documentation is subject to inspection by the Sponsor and regulatory authorities.

#### **14.2. Investigator Reports**

In accordance with the FDA reporting requirements, the investigators will be required to prepare and submit to the Sponsor the following complete, accurate, and timely reports on this investigation when necessary:

- The investigator will notify the Sponsor of a subject death occurring during the investigation as soon as possible, preferably within 24 hours of learning of the subject's death, but in no event later than 48 hours. The investigator will also notify the Sponsor immediately of a serious adverse event, preferably within 48 hours of learning of the serious adverse event, but in no event later than 5 working days.
- The investigator will notify the Sponsor of any unanticipated adverse device effects (UADE) preferably within 48 hours after the investigator first learns of the effect, but in no event later than 5 working days. The investigator will notify its IRB of any unanticipated adverse device effects as soon as possible, but no later than 10 working days after the investigator first learns of the effect.
- The investigator will notify the Sponsor of the withdrawal of IRB approval as soon as possible, but no later than 5 working days after the investigator first learns of the withdrawal
- The investigator will provide current progress reports to the Sponsor and reviewing IRB at regular intervals but at least on an annual basis.
- The investigator will notify the Sponsor and the IRB of any deviation from the investigational plan to protect the life and physical well-being of a subject in an emergency as soon as possible, but no later than 5 working days after the emergency occurred.
- The investigator will notify the Sponsor and IRB that an informed consent was not obtained from a subject as soon as possible, but no later than 5 working days after such an occurrence.

- The investigator will provide a final summary report within 3 months after termination or completion of the trial to the IRB. The site trial completion report may serve as the trial completion for the Sponsor.
- The investigator will provide any other information upon the request of the IRB, or the Sponsor.

### **14.3. Data Collection**

All data required by the trial protocol will be entered into the trial database by the investigator or his or her designate. A copy of draft eCRFs is provided in [Appendix 4](#).

### **14.4. Source Documents**

Original documentation supporting the data recorded on the CRFs must be maintained, and may include clinical charts, medical records, laboratory reports, physician referral or consultation letters, x-ray reports, etc. Adverse events which are managed at a health care facility other than the study site must be reported on the case report form and every attempt must be made to obtain source documentation from that facility.

During monitoring visits, source documents will be reviewed to ensure accuracy and validity of data recorded on the CRFs. Source document verification will be performed by TransMedics or its designee, with due regard to subject confidentiality.

### **14.5. Archiving of Records**

Essential trial documents must be maintained by the Investigator for at least 2 years after the last marketing approval by a regulatory body, as determined by the Sponsor. The documents should be retained for a longer period, however, if required by the applicable regulatory requirements. Records will be kept in a secure, dry location controlled by the institution.

## **15. CLINICAL MONITORING**

### **15.1. Monitoring**

The trial will be monitored by TransMedics. All monitors will be qualified by education, training, and experience. After the study has been initiated, TransMedics or its designee will perform periodic monitoring visits to assess study progress, perform device accountability, assess the adequacy of records, and to ensure adherence to the study protocol. Monitoring visits could be done live or via webconference.

A summary of the monitoring visit, including documentation of completed previous action items and/or new or outstanding action items, and/or significant findings will be provided to the Investigator.

In addition to periodic monitoring visits, TransMedics may perform remote monitoring to ensure data are submitted in a timely manner. Ongoing communication with investigators and study staff will be performed through written correspondence and telephone conversations.

Details related to site monitoring will be documented in the Sponsor's study-specific monitoring plan.

If the investigator is not complying with the signed Investigator Agreement, the protocol, or any condition of the trial, (e.g., incomplete data forms) the Sponsor has the right to terminate the investigator's participation in the trial. The Sponsor's general monitoring procedures for investigational studies are described below.

### **15.2. Site Initiation Visit**

TransMedics or its designee will be responsible for determining and documenting that each investigator clearly understands and accepts the responsibilities and obligations incurred in conducting a clinical study. The sponsor or its designee will ensure, prior to study initiation, that the investigator:

- Understands the requirements for device accountability
- Understands the requirements of the clinical protocol
- Understands reporting obligations
- Understands and accepts the obligations to obtain informed consent
- Understands and accepts the obligation to obtain Institutional Review Board approval of the protocol and informed consent form prior to the enrollment of the first subject.
- Has adequate facilities to conduct the investigation.

Site initiation could be done via webconference.

### **15.3. Periodic Monitoring Visits**

Monitoring visits will be conducted as scheduled by the sponsor. The monitor should visit (or conduct the visit via webconference) with each site as needed to ensure the following:

- Facilities continue to be adequate and acceptable.
- Informed consent has been obtained.
- The protocol is being properly followed.
- The IRB has approved or been notified of any protocol changes.
- Accurate, complete and current records are being maintained, and the information recorded and submitted to the Sponsor is representative of the subject's record and other supporting documentation.
- Accurate, complete and timely adverse event reports are being submitted to the Sponsor.
- The reason for a subject's withdrawal from the trial has been documented.
- Reports are being submitted to the IRB and Sponsor.
- The appropriate staff is carrying out trial activities.

**15.4. Frequency of Monitoring Visits**

The frequency of monitoring visits will be determined on the basis of several factors, including the duration of the trial, number of subjects enrolled, number of investigators/sites, complexity of the trial, and number of outstanding issues from previous visits.

**15.5. Study Close-out Visit**

The study close-out visit may be combined with a monitoring visit. The following tasks will be completed at close-out visit.

- Ensure that all required CRFs have been completed/submitted.
- Ensure final disposition of investigational devices.
- Remind the investigator of the obligation to retain the records in accordance with local country requirements, and prepare a final report for the sponsor and Institutional Review Board.

**15.6. Protocol Deviations**

The study should be conducted as described in this protocol. All deviations from the protocol should be reported to the Sponsor by entering a protocol deviation form into the study database.

For sites who demonstrate repeated deviations that may affect the safety of subjects, and/or the integrity of the data, corrective measures will be instituted such as re-training. Continued protocol deviations may result in the site's termination from the trial.

**15.7. Clinical Events Committee (CEC)**

The Sponsor will utilize an independent Clinical Events Committee (CEC) to provide individual serious adverse event adjudication for the trial. It is anticipated that the CEC will meet with the Sponsor on a periodic basis, or as needed, depending on the rate of patient accrual. The CEC will be guided by the CEC Charter; however, the primary responsibilities of the CEC are to:

- Review reportable serious adverse events, including PGD, that occur over the course of the trial and the subsequent classification of these adverse events as related to the device.
- Provide recommendations to extend the length of follow-up past 30 days post-transplant for a subject experiencing a serious adverse event.

**15.8. Data Safety Monitoring Board & Stopping Rules**

An independent Data Safety Monitoring Board (DSMB) will be established by the Sponsor to periodically assess the progress of the trial, the safety data and the primary efficacy and safety endpoints. The DSMB will make recommendations to the Sponsor regarding continuation, modification or termination of the clinical trial. The DSMB will review all data submitted to them by the Sponsor and may request additional information to assist in their decision process. They will attend scheduled meetings and issue written minutes of their meetings; furthermore, the appointed Chair will be responsible for issuing final written recommendations.

The following stopping rule is to be used in the study:

- **Stopping Rule:** Let  $p$  denote the true proportion of recipients transplanted with an OCS-treated heart for whom the recipient does not survive until Day 30. Whenever a recipient dies within 30 days post-transplant, calculate a 97.5% lower confidence bound for  $p$ . Stop the study if this lower confidence bound exceeds 0.15 (15%).

Table 3 below shows the conditions under which the study would be stopped for a range of number of deaths ( $m$ ) and a range of number of recipients ( $n$ ). (The above stopping rule would, however, be applied to all combinations of number of deaths and number of recipients that were observed in the study.) The word "Stop" in a cell indicates that the study would be stopped if this condition were met. If the word "Continue" appears, the study would continue. A dash indicates an impossible condition, with  $m > n$ . One sees, for example, that the study would be stopped if there were 4 deaths out of the first 5 recipients or 5 deaths out the first 10 recipients.

**Table 3: Conditions under which Study Would be Stopped**

n	M											
	1	2	3	4	5	6	7	8	9	10	11	12
5	Continue	Continue	Continue	Stop	Stop	-	-	-	-	-	-	-
10	Continue	Continue	Continue	Continue	Stop	Stop	Stop	Stop	Stop	Stop	-	-
20	Continue	Continue	Continue	Continue	Continue	Continue	Stop	Stop	Stop	Stop	Stop	Stop
30	Continue	Continue	Continue	Continue	Continue	Continue	Continue	Continue	Continue	Stop	Stop	Stop
40	Continue	Continue	Continue	Continue	Continue	Continue	Continue	Continue	Continue	Continue	Continue	Stop

TransMedics will be responsible for implementing the stopping rule.

### 15.9. Investigator Training

Device, protocol and electronic database training will be provided to the appropriate personnel prior to patient enrollment in the trial. Device training will be conducted at the TransMedics clinical training facility or equivalent training facility. Protocol training will include a thorough review of this protocol. Electronic database training will consist of an explanation of the structure of the database, the data elements to be collected, simulated use of the database, error handling, and instructions regarding the handling of queries.

## 16. CONFIDENTIALITY

All information generated in this trial will be considered highly confidential and must not be disclosed to any persons not directly concerned with the trial without written prior permission from the Sponsor. Authorized regulatory officials and Sponsor personnel (or their representatives) will be allowed full access to inspect and copy the records. All investigational devices, subject bodily fluids, and/or other materials collected shall be used solely in accordance with this protocol, unless otherwise agreed to in writing by the Sponsor. Subjects will be identified only by initials and unique subject numbers on the case report forms. If necessary, their full names may be made known to the Sponsor, a regulatory agency, or other authorized officials.

## 17. AMENDMENT POLICY

The investigator will not make any changes to this protocol without prior written consent from the Sponsor and subsequent approval by the IRB, except if the deviation from the protocol is necessary to protect the life and physical well-being of a subject in an emergency. Such protocol deviations will be reported to the Sponsor and the reviewing IRB as soon as possible, but no later than 5 working days



after the emergency occurred. Protocol amendments will be submitted to the chairman of the IRB responsible for reviewing amendments. Except for “administrative letters,” investigators will await IRB approval of protocol amendments before implementing the change(s).

## 18. REFERENCES

1. Ardehali, et al. Ex-vivo perfusion of donor hearts for human transplantation (PROCEED II): a prospective, open-label, multicenter, randomised non-inferiority trial. *Lancet*. 2015 Jun 27;385(9987):2577-84.
2. Chew, et al. Outcomes of Donation After Circulatory Death Heart Transplantation in Australia. *Journal of the American College of Cardiology*; Vol 73, No.12, 2019.
3. Dhital, et al. Adult heart transplantation with distant procurement and ex-vivo preservation of donor hearts after circulatory death: a case series. *The Lancet*, 2015, 385(9987), 2585-2591.
4. Dhital, et al. Rapid Retrieval and Ex-Situ Portable Machine Perfusion allows Successful Cardiac Transplantation with Donor Hearts from Controlled Donation after Circulatory Death. *J. Heart Lung Transplant*; 2017.
5. García Saéz, et al., Ex vivo heart perfusion after cardiocirculatory death; a porcine model. *J. Surg. Res.*, 2015 May 1; 95(1):311-314, doi: 10.1016/j.jss.2014.12.039. Epub 2014 Dec 23.
6. García Saéz, et al. Heart Transplantation after donor circulatory death in patients bridged to transplant with implantable left ventricular assist devices. *J. Heart Lung Transplant.*; 2016, 35(10): 1255-1260.
7. García Saéz, et al. Donor Circulatory Death Heart Transplantation with Adverse Donor and Recipient Risk Profile. *J. Heart Lung Transplant.*; 2017, 36(45): S16.
8. Hunt, SA, Haddad F. The changing face of heart transplantation. *J. Am. Coll. Cardiol.*; 2008; 52:587-598.
9. Israni, et al. OPTN & SRTR Annual Data Report 2014. *American Journal of Transplantation*; Volume 16, Issue S2, pages 195-215, 11 JAN 2016 DOI: 10.1111/ajt.13673.
10. Iyer, et al., Normothermic Ex Vivo Perfusion provides superior organ preservation and enables viability of hearts from DCD donors. *Am J. Transplant.*, 2015, 15:371-380.
11. Katz, et al. Advanced Therapies for End-Stage Heart Failure. *Current Cardiology Reviews*; 2015, 11:63-72.
12. Kirklin, et al. Eighth Annual INTERMACS Report: Special focus on framing the Impact of Adverse Events. *J. Heart Lung Transplant.*; 2017, 36: 1080-1086.
13. Kobashigawa, et al. Report from a Consensus Conference on Primary Graft Dysfunction after Cardiac Transplantation. *J. Heart Lung Transplant.*; 2014; 33: 327-340.
14. Kobashigawa, et al. Report from the American Society of Transplantation Conference on Donor Heart Selection in Adult Cardiac Transplantation in the United States. *Am J. Transplantation*; 2017; 17:2559-2566.
15. Koerner, M. et al. Normothermic Ex Vivo Allograft Blood Perfusion in Clinical Heart Transplantation. *Heart Surgery Forum*. 2014. 17(3): E144-145.

16. Mancini, D. and Lietz, K. Selection of Cardiac Transplantation Candidates in 2010. *Circulation*; 2010; 122:173-183.
17. Messer, et al. Outcome after Heart Transplantation from Donation after Circulatory-determined Death Donors. *J. Heart. Lung Transplant*; 2017, 36(12):1311-1312.
18. Nicoara, et al. Primary Graft Dysfunction after Heart Transplantation: Incidence, Trends and Associated Risk Factors. *Am. J. Transplant.*; 2018; 18:1461-1470.
19. Peura, et al. on behalf of the American Heart Association Heart Failure and Transplantation Committee, Recommendations for the Use of Mechanical Circulatory Support: Device Strategies and Patient Selection: A Scientific Statement from the American Heart Association. *Circulation*; 2012; 126:2648-2667.
20. Squiers, et al. Application of the International Society for Heart and Lung Transplantation (ISHLT) criteria for Primary Graft Dysfunction after Cardiac Transplantation: Outcomes from a High-Volume Centre. *Euro. J. Cardio-Thoracic Surg*; 2017, 51:263-270.
21. Wilhelm, M.J. Long term outcome following heart transplantation: Current Perspective. *J. Thoracic Dis.*; 2015; 7(3):549-551.

## APPENDIX 1: ISHLT CONSENSUS MANUSCRIPT HEART PRIMARY GRAFT DYSFUNCTION (PGD) (KOBASHIGAWA, ET AL., 2014)

**Table 6** Definition of Severity Scale for Primary Graft Dysfunction (PGD)

<b>1. PGD-Left ventricle (PGD-LV):</b>	<i>Mild PGD-LV: One of the following criteria must be met:</i>	LVEF $\leq 40\%$ by echocardiography, <i>or</i> Hemodynamics with RAP $> 15$ mm Hg, PCWP $> 20$ mm Hg, CI $< 2.0$ L/min/m <sup>2</sup> (lasting more than 1 hour) requiring low-dose inotropes
	<i>Moderate PGD-LV: Must meet one criterion from I and another criterion from II:</i>	I. <i>One</i> criteria from the following: Left ventricular ejection fraction $\leq 40\%$ , <i>or</i> Hemodynamic compromise with RAP $> 15$ mm Hg, PCWP $> 20$ mm Hg, CI $< 2.0$ L/min/m <sup>2</sup> , hypotension with MAP $< 70$ mm Hg (lasting more than 1 hour) II. <i>One</i> criteria from the following: i. High-dose inotropes—Inotrope score $> 10^a$ <i>or</i> ii. Newly placed IABP (regardless of inotropes)
	<i>Severe PGD-LV</i>	Dependence on left or biventricular mechanical support including ECMO, LVAD, BiVAD, or percutaneous LVAD. Excludes requirement for IABP.
<b>2. PGD-right ventricle (PGD-RV):</b>	Diagnosis requires either both i and ii, or iii alone:	i. Hemodynamics with RAP $> 15$ mm Hg, PCWP $< 15$ mm Hg, CI $< 2.0$ L/min/m <sup>2</sup> ii. TPG $< 15$ mm Hg and/or pulmonary artery systolic pressure $< 50$ mm Hg, <i>or</i> iii. Need for RVAD

BiVAD, biventricular assist device; CI, cardiac index; ECMO, extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump; LVAD, left ventricular assist device; PCWP, pulmonary capillary wedge pressure; RAP, right atrial pressure; RVAD, right ventricular assist device; TPG, transpulmonary pressure gradient.

<sup>a</sup>Inotrope score = dopamine ( $\times 1$ ) + dobutamine ( $\times 1$ ) + amrinone ( $\times 1$ ) + milrinone ( $\times 15$ ) + epinephrine ( $\times 100$ ) + norepinephrine ( $\times 100$ )<sup>67</sup> with each drug dosed in  $\mu\text{g/kg/min}$ .

**Note:** All incidences of PGD will be adjudicated by the CEC.

Hemodynamic data will be used in the assessment of PGD severity only if collected by centers as clinically indicated, per the institution's standard of care. This approach is consistent with contemporary U.S. publications on PGD using ISHLT criteria (Nicoara, et al., 2018; Squiers, et al., 2018). If hemodynamic data are not collected, the CEC will use available clinical data to adjudicate PGD severity grading.

**APPENDIX 2: SCHEDULE OF CLINICAL ASSESSMENTS**

Evaluations	Donor & Heart Assessments	
	Acceptance	OCS Preservation
Eligibility & ID	X	
Demographics/Characteristics	X	
Donor Cause of Death	X	
Donor Medical & Social History	X	
Donor Heart Assessment	X	
Donor Cross Clamp Time	X	
OCS Preservation Parameters		X
OCS Lactate Levels		X
Device Malfunction (if applicable)		X
Non-transplant Reasons (if applicable)		X

Evaluations	DCD Transplanted Recipient Schedule of Assessments							
	Day of Tx	T0 <sup>a</sup>	T24	T72	Initial Hospital Discharge	Day 30	Mo 6 <sup>c</sup>	Mo 12 <sup>d</sup>
Eligibility & Informed Consent	X							
Demographics/ Characteristics	X							
Medical & Cardiac History	X							
Transplant Details	X							
PGD Scores			X					
Inotropic Support		X	X					
Right Heart Catheter Results		X <sup>b</sup>	X <sup>b</sup>					
Mechanical Circulatory Support		X	X	X				
Patient & Graft Survival		X	X	X	X	X	X	X
Echocardiogram			X <sup>b</sup>					
Initial ICU Stay					X			
Initial Hospital Stay					X			
HGRSAEs and SAEs	X	X	X	X		X		
Cardiac Allograft Vasculopathy								X <sup>b</sup>

<sup>a</sup> T0 is defined as the time of initial admission to ICU immediately post-heart transplant procedure  
<sup>b</sup> ONLY Tests regularly scheduled per center standard of care or performed due to a clinical cause at these timepoints will be collected.  
<sup>c</sup> Six month follow-up window is  $\pm$  30 days  
<sup>d</sup> Twelve month follow-up window is  $\pm$  60 days

## **APPENDIX 3: DRAFT PATIENT INFORMED CONSENT FORM TEMPLATE**

**(This Page is Intentionally Left Clear)**

## **APPENDIX 4: DRAFT ELECTRONIC CASE REPORT FORMS**

**(This Page is Intentionally Left Clear)**